about
Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X SyndromeHuman Embryonic Stem Cells: A Model for the Study of Neural Development and Neurological DiseasesRNA-binding proteins, neural development and the addictionsAdvances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum DisorderNeuronal RNA-binding proteins in health and diseaseLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related DisordersThe neurobiology of the Prader-Willi phenotype of fragile X syndromeMolecular mechanisms of epilepsyJAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse.The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome.Hierarchical Classes Analysis (HICLAS): A novel data reduction method to examine associations between biallelic SNPs and perceptual organization phenotypes in schizophrenia.A role for dendritic mGluR5-mediated local translation of Arc/Arg3.1 in MEF2-dependent synapse eliminationArbaclofen in fragile X syndrome: results of phase 3 trialsMouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndromeA novel fragile X syndrome mutation reveals a conserved role for the carboxy-terminus in FMRP localization and function.Psychosis and catatonia in fragile X: Case report and literature review.Maternal predictors of anxiety risk in young males with fragile XA de novo microdeletion of SEMA5A in a boy with autism spectrum disorder and intellectual disability.Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders.Co-regulation of mRNA translation by TDP-43 and Fragile X Syndrome protein FMRPModeling neurodevelopmental disorders using human pluripotent stem cells.Anatomy and Cell Biology of Autism Spectrum Disorder: Lessons from Human Genetics.Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops.Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.Fragile X Syndrome FMRP Co-localizes with Regulatory Targets PSD-95, GABA Receptors, CaMKIIα, and mGluR5 at Fiber Cell Membranes in the Eye Lens.Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia.Sequence of Molecular Events during the Maturation of the Developing Mouse Prefrontal Cortex.A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.What, where, and when: the importance of post-transcriptional regulation in the brain.FMRP Mediates Chronic Ethanol-Induced Changes in NMDA, Kv4.2, and KChIP3 Expression in the Hippocampus.The effect of early life status epilepticus on ultrasonic vocalizations in miceBehavioral Markers of Emergent Stranger Anxiety in Infants and Toddlers with Fragile X Syndrome.Gene-set analysis shows association between FMRP targets and autism spectrum disorder.Rapid, experience-dependent translation of neurogranin enables memory encoding.
P2860
Q26739927-99515935-DA12-40CB-B8CA-3BCEAC5C7720Q26745433-06A2E06C-C5B5-4FA9-97FE-4D58B2DAF8C7Q26773909-E67444CB-CB16-4555-B72A-BAE8153A17D0Q26781265-5EFBD282-8456-4F29-9D80-6638206FDC0EQ26866130-E63B8518-96C9-4963-BAE0-453E22CF14BCQ26866506-DE53CD13-1ED4-4EEB-9C87-071A01DF26C2Q28077980-DD0818C0-AE07-456A-ADCB-508669C56D82Q28078294-EBBE1F2D-7EBF-4472-9E27-BAAC5CC404BCQ28087505-CC50E2DD-A7F1-45C1-A230-53FADA35E30BQ28771493-D0CAA209-62D9-4D24-BC24-2D0CB86E8BF4Q30385019-40AC0BA2-A43C-4285-8A28-6D22455F40E1Q30991988-7CB04FA1-0EE4-4509-8FE6-1099CB1C5CB3Q33756913-AEC63F33-8CEA-441C-A680-38A6F8953A1BQ33785963-767E90DB-8C38-44BC-BCE4-7635BC2F1509Q34055453-E96DCE1F-D22C-48FF-98B2-27290EEC336BQ35483780-C393EB05-8E5F-4A1F-BB16-75E96E669087Q35771116-45580433-83BA-416A-B3CF-EB5515085F4DQ36377095-33F715ED-DCAB-4AD7-983C-6010F26CC749Q36902705-D6446A1E-3592-48E2-BA8A-FE4E41468C66Q37286894-C197A842-F8BE-4377-B579-54ECA1750986Q37355103-14C68A7A-7290-44D5-847D-1BD39011FEDDQ38204302-A8A62C95-730F-40F4-B798-78ABA8A047FEQ38678076-50C024E6-8D3E-4EE5-8AF4-FBDD9405FD93Q38777978-9F9CA96A-EE95-411A-B4AE-5A67D6392846Q38921198-590023C8-7A9E-4D2D-ACCC-1964549BD72BQ38971781-EEB7C4F4-587D-48D4-8795-5FEBCF4F5F1BQ39231042-9AB307A2-1E47-438F-B1EC-FC4D964C8C32Q41170329-8403E8C2-C0FB-41DF-8CF8-660D8EF9FF84Q41215871-75B6A056-9300-40B5-A137-F3798380090BQ41647470-595FA22B-6104-468D-B10D-47B47D1E01E8Q41813462-FE8FFC68-EBFE-4B84-9BA1-ADA7D6D9FC50Q41902713-54F59028-16A4-4427-A993-4ADA6A862FB7Q42174298-1C5B75D6-C5A1-40AB-A74D-787FD4B02B6CQ47718870-F0567FDB-7AA0-4399-837C-1EED812B4339Q47745129-DFB0901C-DB8B-4B1B-96CF-4398E3A651CBQ55340003-C1A6454B-F0AD-4A71-A356-83C767699896
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The FMRP regulon: from targets to disease convergence
@ast
The FMRP regulon: from targets to disease convergence
@en
The FMRP regulon: from targets to disease convergence
@nl
type
label
The FMRP regulon: from targets to disease convergence
@ast
The FMRP regulon: from targets to disease convergence
@en
The FMRP regulon: from targets to disease convergence
@nl
prefLabel
The FMRP regulon: from targets to disease convergence
@ast
The FMRP regulon: from targets to disease convergence
@en
The FMRP regulon: from targets to disease convergence
@nl
P2860
P3181
P356
P1476
The FMRP regulon: from targets to disease convergence
@en
P2093
Esperanza Fernández
Nicholas Rajan
P2860
P3181
P356
10.3389/FNINS.2013.00191
P407
P577
2013-10-24T00:00:00Z